UNC Lineberger’s Hyman B. Muss, MD, the Mary Jones Hudson Distinguished Professor in the UNC School of Medicine Division of Hematology/Oncology and director of UNC Lineberger’s geriatric oncology program, led a study published in the Journal of Clinical Oncology that found that older patients with early breast cancer had lower rate of recurrence when treated with standard chemotherapy than with capecitabine.
The study, which updates results of a clinical trial after a median follow-up of 11.4 years, builds on a previous analysis performed after a median follow-up of 2.4 years. It focuses on women aged 65 years and older, since older women with breast cancer remain underrepresented in clinical trials.
Muss was corresponding author of the study. UNC Lineberger’s Lisa A. Carey, MD, FASCO, the Richardson and Marilyn Jacobs Preyer Distinguished Professor in Breast Cancer Research, Division Chief of Hematology and Oncology, and physician-in-chief of the North Carolina Cancer Hospital, was a co-author, along with Lynn D. Dressler, DrPH, research associate professor in the UNC School of Medicine.